CNMD heads into the tail end of July having posted one of its strongest monthly rallies in years, yet the analyst community remains firmly parked on the sidelines — a gap between price action and Street conviction that defines the week's most interesting tension.
The stock closed at $44.25 on Tuesday, up 5.7% on the week and 23% over the past month. That move has carried CNMD well clear of the consensus mean price target of $39.00, which means the average analyst target now implies meaningful downside from current levels rather than upside. The disconnect is stark: BMO Capital initiated coverage in early July with a Market Perform and a $36 target; B of A Securities downgraded to Underperform on June 29, also targeting $40. JP Morgan and Wells Fargo both trimmed targets earlier this year while keeping neutral ratings. The direction of travel across the sell-side has been consistently cautious, and none of those moves have been revised upward to reflect July's rally. Until analyst revisions follow the tape higher, the gap between where CNMD trades and where the Street thinks it belongs will remain the central question for buyers at these levels.
The lending market tells a relaxed story. Borrow availability is extremely loose — roughly 11 shares available for every one currently borrowed, sitting far above the 52-week low of around 412%. Shorts have actually been cutting exposure. Short interest as a percentage of the free float dropped roughly 10.7% over the past week to 7.4% of float, a meaningful step down from the mid-July peak. Cost to borrow runs at just 0.56%, well within normal range and barely changed on the month. The ORTEX short score has drifted lower too, from around 50.6 in mid-July to 47.2 now, suggesting the bears are leaning out rather than pressing. Borrow availability this wide gives anyone wanting to add a short position little urgency — there's no squeeze dynamic building here.
Options positioning has flipped decisively toward calls. The put/call ratio has collapsed from above 2.0 through most of June and early July to just 0.84 now — near the bottom of its 12-month range of 0.11 to 3.16. That shift is dramatic in its speed: the PCR was above 2.0 for nearly three consecutive weeks before breaking sharply lower around July 13. The z-score of -0.48 relative to the 20-day mean of 1.18 confirms options traders have moved from hedging heavily to chasing the rally with calls. The turnaround in sentiment is real, even if it has yet to move sell-side targets.
Valuation multiples have re-rated alongside the price move. The price-to-earnings multiple has expanded by roughly 2.2 turns over the past 30 days to 9.7x, and price-to-book has added 0.22 turns to 1.04x — both reflecting the stock's outperformance. At EV/EBITDA of 7.7x, CNMD is not expensive in absolute terms, and the EV/EBIT factor scores in the 83rd percentile of the universe. Forward EPS estimates are growing strongly on a year-over-year basis, scoring in the 72nd percentile for 12-month forward EPS growth. The bull case centres on BioBrace product momentum and double-digit Foot & Ankle growth; the bear case points to ongoing international capital weakness and a leverage profile that limits flexibility. The dividend history ends in mid-2022, so income is not part of the current thesis. Peers GMED and ZBH both rallied similarly this week — up 5.9% and 7.7% respectively — suggesting the move in CNMD is at least partly a sector-wide re-rating rather than a purely idiosyncratic catalyst.
The earnings data shows CNMD just reported on July 29, the day this note was filed. Whether that print has been absorbed by the Street — and whether it will finally prompt analysts to revise targets toward the current price or double down on their cautious ratings — is the clearest thing to watch in the days ahead.
See the live data behind this article on ORTEX.
Open CNMD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
